HomeCompareFEO vs MRK

FEO vs MRK: Dividend Comparison 2026

FEO yields 20.88% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FEO wins by $15.6K in total portfolio value
10 years
FEO
FEO
● Live price
20.88%
Share price
$9.58
Annual div
$2.00
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73.3K
Annual income
$6,536.52
Full FEO calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — FEO vs MRK

📍 FEO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFEOMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FEO + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FEO pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FEO
Annual income on $10K today (after 15% tax)
$1,774.53/yr
After 10yr DRIP, annual income (after tax)
$5,556.04/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $3,040.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FEO + MRK for your $10,000?

FEO: 50%MRK: 50%
100% MRK50/50100% FEO
Portfolio after 10yr
$65.5K
Annual income
$8,325.15/yr
Blended yield
12.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FEO
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FEO buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFEOMRK
Forward yield20.88%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.8%32.7%
Portfolio after 10y$73.3K$57.7K
Annual income after 10y$6,536.52$10,113.78
Total dividends collected$41.6K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FEO vs MRK ($10,000, DRIP)

YearFEO PortfolioFEO Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,771$2,070.98$11,213$373.04+$1.6KFEO
2$16,117$2,452.04$12,667$512.06+$3.5KFEO
3$20,114$2,868.90$14,439$708.14+$5.7KFEO
4$24,841$3,319.40$16,640$988.16+$8.2KFEO
5$30,381$3,800.71$19,432$1,394.07+$10.9KFEO
6$36,817$4,309.42$23,057$1,992.90+$13.8KFEO
7$44,236$4,841.66$27,889$2,894.79+$16.3KFEO
8$52,726$5,393.22$34,518$4,286.29+$18.2KFEO
9$62,376$5,959.67$43,912$6,494.35+$18.5KFEO
10$73,279$6,536.52$57,714$10,113.78+$15.6KFEO

FEO vs MRK: Complete Analysis 2026

FEOStock

First Trust-abrdn Emerging Opportunity Fund is a closed-ended balanced mutual fund launched and managed by First Trust Advisors L.P. It is co-managed by Aberdeen Asset Management Inc. The fund invests in public equity and fixed income markets of global emerging countries. It seeks to invest in the stocks of companies operating across the diversified sectors. For its fixed income component, the fund invests in government debt securities, corporate bonds, non investment-grade securities, asset-backed securities, credit-linked notes, and credit default swaps. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Barclays Capital Global Emerging Markets Index, FTSE All World Emerging Market Index, and a blended index composed of JPMorgan Emerging Markets Bond Index - Global Diversified (32.5%); JPMorgan Government Bond Index - Emerging Markets (32.5%); MSCI Global Emerging Markets Index (35.0%). First Trust-abrdn Emerging Opportunity Fund was formed on August 28, 2006 and is domiciled in the United States.

Full FEO Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this FEO vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FEO vs SCHDFEO vs JEPIFEO vs OFEO vs KOFEO vs MAINFEO vs JNJFEO vs ABBVFEO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.